Session » Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies

Date: Monday, November 9, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1636

8 Years Follow-Up of a Novel Autoinflammatory Disease: CD59 Malfunction Causes Hemolytic Anemia, Recurrent Guillain-Barre Syndrome, and Strokes in Pediatric Populations and Respond Well to Eculizumab and Pozelimab

9:00AM-11:00AM: Abstract Number: 1633

A Randomized, Double-Blind, Placebo-Controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease

9:00AM-11:00AM: Abstract Number: 1637

Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan

9:00AM-11:00AM: Abstract Number: 1634

Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?

9:00AM-11:00AM: Abstract Number: 1632

Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry

9:00AM-11:00AM: Abstract Number: 1626

Long-Term Follow-Up of Renal Transplantation Due to Lupus Nephritis. Single Universitary Center Experience

9:00AM-11:00AM: Abstract Number: 1630

Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1628

Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)

9:00AM-11:00AM: Abstract Number: 1629

Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)

9:00AM-11:00AM: Abstract Number: 1631

No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program

9:00AM-11:00AM: Abstract Number: 1627

Phase I Trial of High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients with Mild COVID-19: A Study in the Effects of Shifting Public Opinion on Patient Enrollment

9:00AM-11:00AM: Abstract Number: 1639

Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE)

9:00AM-11:00AM: Abstract Number: 1635

Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database

9:00AM-11:00AM: Abstract Number: 1638

Systemic Treatment in Behçet’s Disease According to Clinical Phenotypes. Study of 111 Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].